Personalized Prescribing Inc.

Personalized Prescribing Inc. is a Canadian pharmacogenetics company based in Richmond Hill, Ontario. It provides genetic drug compatibility testing, branded as Rx Report, along with related assessments such as NeuroMapp, IntraMind, Opti-Med, and MTHFR. The company's mission is to create a new standard of patient care in psychiatry based on objective data and clear science, aiming to help patients receive appropriate antidepressants at correct dosages without prolonged medication trials or unnecessary side effects. Its services are delivered by expert psycho-pharmacists who interpret test results and recommend treatments. The company was founded in 2014 by Mark Faiz and two genetic scientists. Faiz's personal experience with a close friend's mental health challenges 30 years ago inspired a 20-year self-education journey, leading to the conviction that mental illness is fundamentally a brain disorder requiring specialized approaches. In 2017, the company recognized that existing genetic testing was not effective for mental health patients, and from 2018 onward developed what it calls "second-generation pharmacogenetics," investigating metabolic genes, brain receptors, and pathway interactions with proprietary algorithms. Personalized Prescribing offers several tests. The flagship Rx Report costs $549 plus HST and includes pharmacokinetic and pharmacodynamic analysis of 59 genes, 104 variations, and over 90 medications, with review by an expert psychopharmacist. IntraMind ($249) aligns genetic blueprint with daily reality for non-medication strategies. Opti-Med ($199) focuses on liver-enzyme clearance for common medications. The MTHFR Test ($99) assesses methylfolate conversion efficiency. ChemoRisk, an oncology toxicity test, is coming soon. The company also offers a free NeuroMapp assessment of current neurochemical profile. The company positions itself as trusted by doctors and patients alike and by Canada's leading insurers, working with major providers to help verify coverage. It emphasizes clinical decision support through NeuroMapp, which analyzes current symptoms to understand brain circuit functioning and compares this with genetic baseline to identify a "Biological Gap." The test analysis takes 5-7 business days after receiving a swab sample, and results are accessed via a secure online portal. The company claims 99.99% accuracy for the genetic test analysis, with interpretation by pharmacists based on scientific evidence.

Personalized Prescribing Inc. was founded in 2014 by Mark Faiz and two genetic scientists. The founder's journey began 30 years ago when a close friend's life was impacted by mental health challenges. This inspired a 20-year self-education journey, ultimately convincing him that mental illness is fundamentally a brain disorder requiring specialized approaches. In 2017, the company recognized that existing genetic testing wasn't effective for mental health patients. From 2018 to the present, it developed "second-generation pharmacogenetics," investigating metabolic genes, brain receptors, and pathway interactions with proprietary algorithms. The company is based in Richmond Hill, Ontario, Canada, and offers a range of pharmacogenetic tests and clinical decision-support tools.

• 2018

  Began developing "second-generation pharmacogenetics" investigating metabolic genes, brain receptors, and pathway interactions with proprietary algorithms.

• 2017

  Recognized existing genetic testing wasn't effective for mental health patients.

• 2014

  Mark Faiz and two genetic scientists founded a pharmacogenetic testing company.

Clinical decision-support pharmacogenetics for mental health, trusted by doctors, patients, and Canadian insurers.

• Rx Report

  Pharmacist-assisted genetic drug compatibility test; pharmacokinetic and pharmacodynamic analysis of 59 genes, 104 variations, 90+ medications; includes review by an expert psychopharmacist; $549 plus HST.

• NeuroMapp

  Free assessment of current neurochemical profile; clinical decision-support tool that analyzes symptoms to understand brain circuit functioning and compares with genetic baseline to identify Biological Gap.

• IntraMind

  Aligns genetic blueprint with daily reality; maps gap between biology and current symptoms; personalized nutrition, lifestyle, and cognitive protocols; $249.

• Opti-Med

  Liver-enzyme (pharmacokinetic) focus; estimates clearance for more than 80% of common medications; CPIC highest-evidence gene-drug pairs only; $199.

• MTHFR Test

  Focused single-gene test; reveals methylfolate conversion efficiency; actionable guidance for supplementation decisions; $99.

• ChemoRisk

  Coming soon; genetic screening for chemotherapy toxicity risk.

1. 1Personalized Prescribing - Find Your Best-Fit Medicationpersonalizedprescribing.com
2. 2Personalized Prescribing - FAQspersonalizedprescribing.com
3. 3Personalized Prescribing - About Uspersonalizedprescribing.com
4. 4Our Tests | Personalized Prescribingpersonalizedprescribing.com
5. 5Wikidata: Personalized Prescribing Inc. (Canada)wikidata.org